Colgate-Palmolive (CL) FY2025 10-K Annual Report
Colgate-Palmolive (CL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 23, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Colgate-Palmolive FY2025 10-K Analysis
Business Overview
- • Two-segment model: Oral/Personal/Home Care (77% combined net sales) and Pet Nutrition (23%), sold in 200+ countries
- • New C-suite hires: Shane Grant (COO Americas, ex-Danone) and John Hazlin (Chief Growth Officer) added in 2025
- • Explicit strategic emphasis on AI, social commerce, and omni-channel demand generation as growth drivers vs prior year
- • ~33,600 employees across 100+ countries; 84% outside the US, with Asia Pacific (33%) and Latin America (31%) as largest regions
- • Colgate owns "world's most penetrated brand" — household penetration cited as a core KPI of 2030 business strategy
Management Discussion & Analysis
- • Revenue $20,382 in 2025, up 1.4% YoY; organic sales +1.4% driven by 2.1% net pricing, offset by -0.4% volume and -0.3% FX
- • GAAP operating margin 16.2% vs 21.2% (−500 bps) due to $919 pretax Filorga impairment; non-GAAP operating margin 21.3% vs 21.7% (−40 bps); gross margin 60.1% vs 60.5%
- • Best segment: Hill's Pet Nutrition — operating margin 23.1% vs 21.5% (+160 bps), revenue +2.9% to $4,613; worst: North America — revenue −1.6% to $4,045, operating margin 19.4% vs 20.4% (−100 bps)
- • Operating cash flow $4,198 (+2% YoY); capex $564; dividends $1,823 ($2.06/share); share buybacks $1,210 (13.7M shares); new $5B repurchase program authorized March 2025
- • Management expects 2025 category softness to persist into 2026; key risks include tariff-driven cost inflation, FX volatility, China weakness, and private-label trade-down; new Strategic Growth and Productivity Program targets $200–$300 pretax charges through 2028
Risk Factors
- • FDA and global regulators reviewing fluoride, titanium dioxide, synthetic colors, and PFAS in consumer products — reformulation or restriction could materially impact core product lines
- • Eurasia operations ~1% of consolidated net sales and ~2% of consolidated operating profit; cash repatriation from Russia blocked and financial institution access constrained
- • Single-source or limited-supplier dependencies for key raw/packaging materials; new supplier qualification requires significant time and capital investment
- • eCommerce and AI enabling direct-to-consumer competitors; key retailers leveraging AI-aided pricing algorithms and first-party data to pressure Colgate's shelf access and margins
- • Q4 2025 non-cash after-tax impairment charge of $794M on skin health business goodwill and intangible assets, signaling acquisition integration risk
Colgate-Palmolive FY2025 Key Financial MetricsXBRL
Revenue
$20.4B
▲ +1.4% YoY
Net Income
$2.1B
▼ -26.2% YoY
Gross Margin
60.1%
▼ -39bp YoY
Operating Margin
16.2%
▼ -501bp YoY
Net Margin
10.5%
▼ -391bp YoY
ROE
3948.1%
▲ +258541bp YoY
Total Assets
$16.3B
▲ +1.8% YoY
EPS (Diluted)
$2.63
▼ -25.1% YoY
Operating Cash Flow
$4.2B
▲ +2.2% YoY
Source: XBRL data from Colgate-Palmolive FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Colgate-Palmolive
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.